Arrowhead Pharmaceuticals (ARWR) Capital Expenditures (2011 - 2026)

Arrowhead Pharmaceuticals' Capital Expenditures history runs 16 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• Quarterly Capital Expenditures fell 74.95% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$7.8 million (down 115.18% YoY) and the FY2025 annual result came in at $277000.0, down 99.8% from the prior year.
• Capital Expenditures was $2.6 million for Q1 2026 at Arrowhead Pharmaceuticals, up from $2.1 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $161.1 million in Q3 2023 and bottomed at -$50.6 million in Q2 2023.
• A 5-year average of $21.8 million and a median of $10.2 million in 2025 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2022 — Capital Expenditures jumped 573.43% — and 2023, when it slumped 630.63%.
• Arrowhead Pharmaceuticals' Capital Expenditures stood at $38.9 million in 2022, then soared by 76.44% to $68.7 million in 2023, then sank by 96.25% to $2.6 million in 2024, then slipped by 16.55% to $2.1 million in 2025, then gained by 19.41% to $2.6 million in 2026.
• Business Quant data shows ARWR's Capital Expenditures at $2.6 million in Q1 2026, $2.1 million in Q4 2025, and -$69000.0 in Q3 2025.